First results of Russian multicenter prospective clinical study VICTORY II: Vamloset® and Co-Vamloset effectiveness and safety in patients with stage 2 and 3 arterial hypertension

VICTORY II study objective. Evaluation of Vamloset and Co-Vamloset safety and effectiveness in reaching target blood pressure (BP) level in patients with stages 2-3 arterial hypertension (AH). Materials and methods. Russian multicenter prospective clinical study conducted in 8 clinical centers in 6 cities in Russian Federation included 103 patients over 18 years of age with diagnosed essential hypertension of stages 2-3 (in accordance with 2013 European guidelines) who previously did not receive treatment (with office systolic BP - sBP≥160 mm Hg and/or office diastolic BP - dBP≥100 mmHg) or did not achieve target BP levels after receiving mono- or dual therapy. Office BP target levels comprised ≤139 mmHg for sBP and ≤89 mm Hg for dBP for patients without diabetes mellitus (DM), and ≤139 mm Hg for sBP and ≤84 mm Hg for dBP for patients with DM. All patients with stage 2 AH (group 1) were prescribed Vamloset® (amlodipine/valsartan, 5/80 mg), patients with stage 3 AH - Vamloset® -(amlodipine/valsartan, 5/160 mg). Therapy correction Vamloset® (amlodipine/valsartan) in doses 5/160 mg, 10/160 mg and Co-Vamloset (amlodipine/valsartan/hydrochlorothiazide) in doses 10/160/12,5 mg, 10/160/25 mg (“КРКА-RUS”) was performed every 4 weeks according to provided schemes. At follow-up every 4 weeks the decision on necessity of antihypertensive treatment (AHT) correction were made by medical researcher in accordance with analysis of patients’ complaints, general condition and physical examination, results of office BP measurement, diary of BP self-control. In 40 patients in subgroup with additional assessment 24-hour BP monitoring, pulse wave velocity measurement, central BP evaluation, augmentation index calculation, and endothelium damage markers determination were performed. Results. Active phase of the study included 100 patients aged 59.5±10.9 years (59% female) suffering from AH for 83.4±8.4 months. The patients received treatment with study medication (safety population). The protocol population (sampling Per Protocol) included 80 patients who completed the study without severe protocol violation. At the moment of study entrance 83% of patients received AHT. In all patients treatment duration comprised 15.9 weeks. In Per Protocol population target office BP level was achieved by 90.0% (95% confidence interval 81.2-95.6%) of the patients. Overall clinical effectiveness (extremely high, very high, high, and sufficient) was achieved in 98.8% [95% confidence interval 93.2-100%] of the patients. In group of patients with stage 2 AH target office BP level was achieved by 93.8% of patients, in group with stage 3 AH - by 84.4% of patients. Mean BP change in study group was -32.2 mm Hg for SBP and -16.0 mm Hg for DBP. Among patients with stage 2 AH target office BP level was achieved by 93.8% of patients, with mean BP change -30,7 mm Hg for SBP and -15.5 mm Hg for DBP. In patients with stage 3 AH target BP levels were achieved in 84.4% of patients with mean BP change -34,6 mm Hg for SBP and -16.7 mm Hg for DBP. After 16 weeks of treatment in Full Analysis Set population with recovery of missed measures using Last Observation Carried Forward 40.2% of patients reached target BP levels according to BP self-control results. Considering the limitations of results evaluation this practice requires further assessment, standardization, and improvement. According to 24-hour BP monitoring reaults after 16 weeks of treatment 26.5% of patients achieved target BP daily profile (for patients from subgroup with additional assessment in Full Analysis Set population with recovery of missed measures using Last Observation Carried Forward), that indicates additional influence of studied AHT on the prognosis of patients with stages 2-3 AH. Conclusion. In clinical study VICTORY II Vamloset® and Co-Vamloset optimal effectiveness and safety in patients with stage 2 and 3 arterial hypertension were shown.

VICTORY II

1. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39: 3021-104.

2. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281-357.

3. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.

4. Шальнова С.А., Конради А.О., Карпов Ю.А. и др. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании «Эпидемиология сердечно-сосудистых заболеваний в различных регионах России». Рос. кардиол. журн. 2012; 5: 6-11.

5. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1): 6-31.

6. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual datafor one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.

7. De Buyzere ML, Clement DL. Management of hypertension in peripheral arterial disease. Prog Cardiovasc Dis 2008; 50: 238-63.

8. Леонова М.В, Штейнберг Л.Л., Белоусов Ю.Б. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии Пифагор IV: приверженность врачей. Рос. кардиол. журн. 2015; 1: 59-66.

9. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290-300.

10. Чазова И.Е., Мартынюк Т.В. от имени группы российских исследователей. Первые результаты международного клинического исследования VICTORY: эффективность и безопасность антигипертензивной монотерапии валсартаном и его фиксированной комбинации с гидрохлоротиазидом в разных дозовых режимах у пациентов с артериальной гипертонией 1-2-й степени. Системные гипертензии. 2015; 12 (2): 71-82.

11. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012; 32: 649-64.

12. Matsuzaki M, Ogihara T, Umemoto S et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29: 1649-59.

13. Колос И.П., Мартынюк Т.В., Сафарян А.С. и др. Изучение эффективности терапии ингибитором ангиотензин-прекращающего фермента рамиприлом и его комбинации с гидрохлортазидом у пациентов с артериальной гипертонией избыточной массой тела: исследование ХАРИЗМА. Кардиоваск. терапия и профилактика. 2008; 7 (2): 65-71.

14. Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-51.

15. Мацкевич С.А., Барбук О.А. Применение валсартана (валзан Н) в лечении пациентов с артериальной гипертензией. Мед. новости. 2013; 3: 60-3.

16. MacDonald TM, Williams B, Webb DJ et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017; 6: e006986.